Pfizer on Tuesday said it agreed to buy the rest of Biohaven Pharmaceutical Holding for about $11.6 billion, giving the New York drugmaker full ownership of the Nurtec ODT migraine franchise.
Pfizer said it would pay $148.50 a share in cash for the Biohaven shares that it doesn’t already own, a nearly 79% premium to Monday’s closing price of $83.14 for the New Haven, Conn., biopharmaceutical company.
To Read the Full Story
